Another meta-analysis by Nguyen et al. (2022) has found that the treatment with GLP-1 agonists is effective in decreasing mortality among diabetic T2 patients infected with COVID-19 [OR 0.51, 95% CI (0.37–0.69)] [12]. The gene discussed is GCG; the disease is COVID-19.